Inside Precision Medicine June 5, 2024
Just as 23andMe, once direct-to-consumer (DTC) testing’s darling, faced a huge drop in share value and once hot startup LunaDNA was shuttering, Panacea was promoting its new DTC genetic testing service.
This might seem counter-intuitive, but consumer genetics is far from dead, even the DTC version.
Panacea, for example, says it has some new twists—including exome sequencing at an affordable price—that will make a big difference. And 23andMe isn’t giving up, rather they are forging ahead, with new offerings such as an updated BRCA1/BRCA2 test and a deeper push into drug discovery. CEO Anne Wojcicki, told CNN in February, “We’re making the necessary changes to make the business sustainable, and then it’s going to be about growing it again.”
Traditional...
Today's Sponsors
Today's Sponsor